# Core F: Biomarker Core

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $372,611

## Abstract

ABSTRACT – CORE F: BIOMARKER CORE
Biomarkers are becoming instrumental components of effective clinical management and trial coordination for
Alzheimer’s disease and related dementias (ADRD), and will be required to enable precision medicine
approaches to diagnosis and treatment. The primary functions of the newly added Biomarker Core (BC) of the
Michigan Alzheimer’s Disease Research Center (MADRC) will be to facilitate innovative research into
established and novel blood biomarkers, and provide expertise and access to biomarker assay technologies
for investigators at the University of Michigan, Michigan State University, Wayne State University, as well as
other ADRCs. The overall goal of the BC is to use cutting-edge ultrasensitive ELISA and quantitative mass
spectrometry (MS) approaches to measure biomarkers in blood, identify and build novel blood-based
biomarker assays, and integrate biomarkers with clinical measures of disease. We will leverage MADRC
resources from ongoing and future efforts to achieve this goal and promote studies that align with the
MADRC’s central theme to identify, understand and modulate the many factors beyond β-amyloid contributing
to ADRD. The diverse patient population in the MADRC’s longitudinal cohort and other ongoing clinical
research efforts, coupled with the ability to develop novel biomarker assays, will significantly enhance the
ability of the BC to focus on unique questions regarding the extent to which current and novel biomarker
targets enhance diagnostic accuracy, and track disease progression and predictability over time in multiple
patient populations, including underrepresented racial/ethnic groups. The BC will pursue the following five
aims: 1) provide measurements of established blood biomarkers, 2) develop and implement novel biomarker
assays, 3) facilitate integration of blood biomarkers with established clinical practices to advance translational
research, 4) contribute blood biomarker data to the National Alzheimer’s Coordinating Center, and 5) educate
and train health care professionals, scientists and students in the use of biomarker assays. The BC goals and
aims will be achieved by working closely with the MADRC Clinical Core, Data Management and Statistical
Core, Neuroimaging Core, Neuropathology Core, and Research Education Component. Through these efforts,
the BC will markedly enhance research supported by the MADRC, leading to a sustained and significant
impact for the field as we build a comprehensive assessment of the diagnostic and the predictive utility of
blood-based biomarker profiles. We will also interface with other ADRCs and investigators to help shape an
evolving clinical landscape for dementia evaluation and treatment.

## Key facts

- **NIH application ID:** 10261114
- **Project number:** 1P30AG072931-01
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Nicholas M Kanaan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $372,611
- **Award type:** 1
- **Project period:** 2021-09-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10261114

## Citation

> US National Institutes of Health, RePORTER application 10261114, Core F: Biomarker Core (1P30AG072931-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10261114. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*